CME

This activity is supported by an educational grant from Genentech, Inc.

Combination Strategies in Melanoma Management: What’s New and What’s Next

Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Overview

Author(s)/Faculty: Antoni Ribas, MD, PhD; Caroline Robert, MD, PhD
Source: Healio - Hematology/Oncology Education Lab
Type: LectureArticles/Items: 3
Release Date: 1/24/2017Expiration Date: 1/24/2018
Credit Type: CMENumber of Credits: 0.75
Cost: FreeProvider: Vindico Medical Education
Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is often curable if caught early, treatment options are limited for patients with advanced disease. In almost all cases, death is caused by widespread metastatic disease. Fortunately, an improved understanding of the genetic impact of the disease, earlier detection, appropriate staging, and a treatment revolution that has brought new targeted as well as immunotherapies to clinic has dramatically improved outcomes for patients with metastatic melanoma. In this CME activity, leading oncologists will discuss the latest treatment strategies, clinical advances, as well as clinical evidence for sequencing and combining targeted therapies for the treatment of BRAF-positive metastatic melanoma.

CME Information

page 1 of 6